NVDA
NVIDIA
-- 115.430 TSLA
Tesla
-- 225.310 INTC
Intel
-- 25.920 PLTR
Palantir
-- 83.890 BABA
Alibaba
-- 142.740 
News
$Zomedica (ZOM.US)$ Zomedica Launches New Canine Tests for Faster Heart Disease Detection
Benzinga· 1 min ago
Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.
Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the diagnosis and management of cardiac conditions in dogs. This test distinguishes cardiac from respiratory disease, identifies dogs at high risk of congestive heart failure, aids with chronic monitoring of dogs with myxomatous mitral valve degeneration all with reference lab accuracy.
Benzinga· 1 min ago
Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.
Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the diagnosis and management of cardiac conditions in dogs. This test distinguishes cardiac from respiratory disease, identifies dogs at high risk of congestive heart failure, aids with chronic monitoring of dogs with myxomatous mitral valve degeneration all with reference lab accuracy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
J Servai (JLAPT) : $Zomedica (ZOM.US)$ ....